LONDON: The Oxford/AstraZeneca vaccine fails to prevent mild and moderate cases of the South African coronavirus strain, researchers said Sunday.
The University of Witwatersrand, Johannesburg, which conducted the trial, said in a statement that the vaccine “provides minimal protection against mild-moderate Covid-19 infection” from the variant.
But in a full paper due to be published on Monday, AstraZeneca said that none of the 2,000 participants developed serious symptoms.
That could mean it will still have an effect on severe disease, although there is not yet enough data to make a definitive judgement.
The data, which has not yet undergone peer review, “appear to confirm the theoretical observation that mutations in the virus seen in South Africa will allow ongoing transmission of the virus in vaccinated populations”, it said. “Protection against moderate-severe disease, hospitalisation or death could not be assessed in this study as the target population were at low risk.”
But the vaccine developers in Britain said informally the results offered some hope that the vaccine could prevent deaths from the variant.
Britain is in the midst of a massive vaccination drive, which it sees as its way out of one of the worst outbreaks in the world that has seen more than 112,000 fatalities among those testing positive for the virus.
It has so far vaccinated more than 11 million people using either the Pfizer/BioNTech or Oxford/AstraZeneca shots.
The AstraZeneca vaccine has been the source of an ugly row with the European Union, which is angry that the Anglo-Swedish firm was unable to meet the delivery target agreed with Brussels.
France, Germany and Switzerland are also among countries to recommend the vaccine not be used for the elderly due to a lack of data.
Comments
Comments are closed.